Potassium Citrate
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
Potassium Citrate: Familial visceral myopathy
One-Sentence Summary
Potassium citrate is an alkalinizing potassium salt that is marketed in Canada as a single-ingredient product. The TxGNN model predicts it may be relevant to familial visceral myopathy, with a score of 0.9995. There are currently no clinical trials and no publications supporting this prediction, so it rests on the model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Familial visceral myopathy |
| TxGNN Prediction Score | 0.9995 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available for potassium citrate. It is an alkali and potassium salt, and the citrate component can act as a systemic alkalinizing agent.
No mechanistic rationale is evident for familial visceral myopathy beyond the high model score. The prediction may reflect generic associations with electrolytes or smooth-muscle function. It is not supported by any trial, publication, or documented biological link, and it should be treated as a hypothesis only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02353997 | UROCIT-K | Not specified | Not specified in the data compiled for this report |
Safety Considerations
- Drug Interactions: The interaction screening returned 100 records. Major-level interactions include:
- Antihistamines: chlorpheniramine, acrivastine, phenyltoloxamine
- Anticholinergics: methscopolamine, hyoscyamine, homatropine, atropine
- Potassium-raising or renally active agents: amiloride, benazepril, olmesartan, valsartan
- Tricyclic antidepressant: amitriptyline
Moderate-level interactions include doxycycline, ketorolac, ibuprofen, acetylsalicylic acid, aliskiren, pseudoephedrine, amphetamine and dextroamphetamine.
Please refer to the package insert for further safety information, including warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting clinical trials or publications and no plausible mechanistic link, so it remains at the model-prediction level (L5).
To proceed, the following is needed:
- Package insert warnings and contraindications from Health Canada
- Mechanism of action data
- A documented biological rationale linking potassium citrate to visceral smooth-muscle dysfunction
- Any preclinical or clinical evidence directly addressing familial visceral myopathy
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.